Pharmaceutical company AstraZeneca said its drug to treat extensive-stage small cell lung cancer had been approved in China.
The approval by China’s National Medical Products Administration was based on positive results from the CASPIAN Phase 3 trial, which showed that Imfinzi plus chemotherapy “demonstrated a statistically significant and clinically meaningful improvement in overall survival versus chemotherapy alone”.
“In addition, results from the China cohort of patients were consistent with the global results,” Astra said on Monday.
